Janusmed kön och genus

Janusmed kön och genus – Mabthera

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index



Klass : C

  1. Ng CM, Bruno R, Combs D, Davies B. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol. 2005;45(7):792-801.
  2. Müller C, Murawski N, Wiesen MH, Held G, Poeschel V, Zeynalova S et al. The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood. 2012;119(14):3276-84.
  3. Pfreundschuh M, Müller C, Zeynalova S, Kuhnt E, Wiesen MH, Held G et al. Suboptimal dosing of rituximab in male and female patients with DLBCL. Blood. 2014;123(5):640-6.
  4. Jäger U, Fridrik M, Zeitlinger M, Heintel D, Hopfinger G, Burgstaller S et al. Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. Haematologica. 2012;97(9):1431-8.
  5. Cornec D, Kabat BF, Mills JR, Cheu M, Hummel AM, Schroeder DR et al. Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis. Rheumatology (Oxford). 2018;57(4):639-650.
  6. Junlén HR, Peterson S, Kimby E, Lockmer S, Lindén O, Nilsson-Ehle H et al. Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry study. Leukemia. 2015;29(3):668-76.
  7. Yıldırım M, Kaya V, Demirpençe Ö, Paydaş S. The role of gender in patients with diffuse large B cell lymphoma treated with rituximab-containing regimens: a meta-analysis. Arch Med Sci. 2015;11(4):708-14.
  8. Gisselbrecht C, Schmitz N, Mounier N, Singh Gill D, Linch DC, Trneny M et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol. 2012;30(36):4462-9.
  9. Carella AM, de Souza CA, Luminari S, Marcheselli L, Chiappella A, di Rocco A et al. Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study. Leuk Lymphoma. 2013;54(1):53-7.
  10. Zhou Z, Rademaker AW, Gordon LI, LaCasce AS, Crosby-Thompson A, Vanderplas A et al. High Body Mass Index in Elderly Patients With DLBCL Treated With Rituximab-Containing Therapy Compensates for Negative Impact of Male Sex. J Natl Compr Canc Netw. 2016;14(10):1274-1281.
  11. Gang AO, Pedersen M, d'Amore F, Pedersen LM, Jensen BA, Jensen P et al. A clinically based prognostic index for diffuse large B-cell lymphoma with a cut-off at 70 years of age significantly improves prognostic stratification: population-based analysis from the Danish Lymphoma Registry. Leuk Lymphoma. 2015;56(9):2556-62.
  12. Riihijärvi S, Taskinen M, Jerkeman M, Leppä S. Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy. Eur J Haematol. 2011;86(2):124-8.
  13. Ngo L, Hee SW, Lim LC, Tao M, Quek R, Yap SP et al. Prognostic factors in patients with diffuse large B cell lymphoma: Before and after the introduction of rituximab. Leuk Lymphoma. 2008;49(3):462-9.
  14. Pfreundschuh M, Murawski N, Zeynalova S, Ziepert M, Loeffler M, Hänel M et al. Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients. Br J Haematol. 2017;179(3):410-420.
  15. Lin TL, Kuo MC, Shih LY, Dunn P, Wang PN, Wu JH et al. The impact of age, Charlson comorbidity index, and performance status on treatment of elderly patients with diffuse large B cell lymphoma. Ann Hematol. 2012;91(9):1383-91.
  16. Sawalha Y, Rouphail B, Jia X, Dean RM, Hill BT, Jagadeesh D et al. Is rituximab sub-optimally dosed in indolent B cell lymphoma?. Br J Haematol. 2016;174(5):721-9.
  17. Abrahamsson A, Albertsson-Lindblad A, Brown PN, Baumgartner-Wennerholm S, Pedersen LM, D'Amore F et al. Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study. Blood. 2014;124(8):1288-95.
  18. Marangon M, Vianelli N, Palandri F, Mazzucconi MG, Santoro C, Barcellini W et al. Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response. Eur J Haematol. 2017;98(4):371-377.
  19. Chapin J, Lee CS, Zhang H, Zehnder JL, Bussel JB. Gender and duration of disease differentiate responses to rituximab-dexamethasone therapy in adults with immune thrombocytopenia. Am J Hematol. 2016;91(9):907-11.
  20. Tun NM, Villani GM. Efficacy of rituximab in acute refractory or chronic relapsing non-familial idiopathic thrombotic thrombocytopenic purpura: a systematic review with pooled data analysis. J Thromb Thrombolysis. 2012;34(3):347-59.
  21. Andrès E, Mecili M, Fothergill H, Zimmer J, Vogel T, Maloisel F. Gender-related analysis of the clinical presentation, treatment response and outcome in patients with immune thrombocytopenia. Presse Med. 2012;41(1):e426-31.
  22. Lee LJ, Toze CL, Huang SJT, Gillan TL, Connors JM, Sehn LH et al. Improved survival outcomes with the addition of rituximab to initial therapy for chronic lymphocytic leukemia: a comparative effectiveness analysis in the province of British Columbia, Canada. Leuk Lymphoma. 2018;59(6):1356-1363.
  23. Couderc M, Gottenberg JE, Mariette X, Pereira B, Bardin T, Cantagrel A et al. Influence of gender on response to rituximab in patients with rheumatoid arthritis: results from the Autoimmunity and Rituximab registry. Rheumatology (Oxford). 2014;53(10):1788-93.
  24. Choi YW, Jeong SH, Ahn MS, Lee HW, Kang SY, Choi JH et al. Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP. J Korean Med Sci. 2014;29(11):1493-500.
  25. Lang DS, Keefe DM, Schultz T, Pearson A. Predictors of acute adverse events from rapid rituximab infusion. Support Care Cancer. 2013;21(8):2315-20.
  26. Wadström H, Frisell T, Askling J, Anti-Rheumatic Therapy in Sweden (ARTIS) Study Group. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden. JAMA Intern Med. 2017;177(11):1605-1612.
  27. Concise. Kalmar: eHälsomyndigheten. 2015 [cited 2018-07-20.]